Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

thyrointegrin alphaVbeta3 antagonist fb-PMT

A fluorobenzyl polyethylene glycol (PEG) conjugated to tetraiodothyroacetic acid that targets the thyrointegrin alphaVbeta3, with potential antineoplastic activity. Upon administration, the thyrointegrin alphaVbeta3 antagonist fb-PMT targets and binds to alphaVbeta3 integrin. This results in the inhibition of angiogenesis and metastasis. The mechanism of actions (MOAs) through which fb-PMT exerts its actions may be more complex and may be through multiple signaling pathways. AlphaVbeta3 integrin, a cell adhesion and signaling receptor, is overexpressed on the surface of tumor vessel endothelial cells, some tumor cells, and a number of other cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:alphaV/beta3 antagonist fb-PMT
fluorobenzyl polyethylene glycol-conjugated tetraiodothyroacetic acid
Abbreviation:fb-PMT
Code name:NP 100
NP 751
NP-100
NP-751
NP100
NP751
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search